Roche Holding AG (ROP.SW)
Healthcare • Drug Manufacturers - General
StockSwissSwitzerlandCH1499059983
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Roche Holding AG, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in CHF. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 11:33. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 28 Jan 2027 11:00 | — | — | — | Upcoming |
| 21 Jul 2021 22:00 | 10.24 | 3.49 | -65.9% | Miss |
| 21 Jul 2016 01:00 | 7.54 | 2.89 | -61.7% | Miss |
| 02 Feb 2011 16:00 | 6.12 | 2.04 | -66.7% | Miss |
| 14 Oct 2010 01:00 | — | 2.04 | — | — |
| 22 Jul 2010 19:00 | 6.89 | 6.59 | -4.4% | Miss |
| 21 Oct 2008 10:00 | 0.81 | 2.08 | +156.8% | Beat |
Annual results · CHF
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 63.4B | +1.5% | 12.9B | 20.3% | 16.04 | +55.6% | 13.1B |
| 2024 | 62.4B | +3.2% | 8.3B | 13.3% | 10.31 | -28.0% | 15.1B |
| 2023 | 60.4B | -8.2% | 11.5B | 19.0% | 14.31 | -6.9% | 11.4B |
| 2022 | 65.8B | — | 12.4B | 18.9% | 15.37 | — | 13.3B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 398.60 | 407.60 | 380.30 | 404.40 | +0.25% | 9,976,223 | |
| Oct 2026 | 345.00 | 405.90 | 342.50 | 403.40 | +15.55% | 21,918,811 | |
| Sep 2026 | 348.80 | 368.20 | 343.10 | 349.10 | -1.05% | 21,176,660 | |
| Aug 2026 | 355.60 | 375.80 | 351.80 | 352.80 | -0.23% | 18,392,140 | |
| Jul 2026 | 332.80 | 371.20 | 324.00 | 353.60 | +6.25% | 19,645,792 | |
| Jun 2026 | 326.40 | 338.80 | 306.40 | 332.80 | +1.06% | 27,431,528 | |
| May 2026 | 317.90 | 337.40 | 313.00 | 329.30 | +3.42% | 13,821,810 | |
| Apr 2026 | 319.40 | 326.70 | 310.40 | 318.40 | +1.18% | 18,955,483 | |
| Mar 2026 | 365.30 | 365.30 | 291.00 | 314.70 | -14.25% | 29,015,397 | 9.8000 |
| Feb 2026 | 348.00 | 374.90 | 347.10 | 367.00 | +4.65% | 20,414,978 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in CHF, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis (opens in a new tab) Investor's Business Daily · 10 Nov 2026 22:12
- Roche (SWX:ROP) Stock May Be Below Fair Value On FDA Test Clearance (opens in a new tab) Simply Wall St. · 08 Nov 2026 03:17
- Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal (opens in a new tab) Simply Wall St. · 04 Nov 2026 04:33
- Roche Secures FDA Clearance for New cobas eplex Respiratory Panel Detecting Up to 19 Pathogens (opens in a new tab) InvestorsHub · 02 Nov 2026 15:57
- UBS sees Roche giredestrant potential priced in after 50% share rally (opens in a new tab) Investing.com · 02 Nov 2026 11:33
- FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight (opens in a new tab) Stocktwits · 02 Nov 2026 10:36
- Roche Holding (SWX:ROP) Expands ADC Pipeline As Late Stage Trial Results Impress (opens in a new tab) Simply Wall St. · 01 Nov 2026 14:05
- Roche Holding (SWX:ROP) Could Be 55% Undervalued Following Its Global BAP1 Test Launch (opens in a new tab) Simply Wall St. · 29 Oct 2026 07:15
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 406.50 CHF
- Market cap
- 323.9B
- Dividend yield
- 2.41%
- 5-year average yield
- 3.22%
- Payout ratio
- 64%
- Last dividend
- 9.8000 CHF · 12 Mar 2026
- Exchange
- Swiss
- Country
- Switzerland
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- CHF
Dividends
| Ex-dividend date | Per share |
|---|---|
| 12 Mar 2026 | 9.8000 CHF |
| 27 Mar 2025 | 9.7000 CHF |
| 14 Mar 2024 | 9.6000 CHF |
| 16 Mar 2023 | 9.5000 CHF |
| 8 older dividends: create a free account to see them | |
Why this score
Similar shares
Follow ROP.SW and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.